Your browser is no longer supported. Please, upgrade your browser.
CUE Cue Biopharma, Inc. monthly Stock Chart
Cue Biopharma, Inc.
Index- P/E- EPS (ttm)-1.57 Insider Own3.00% Shs Outstand29.65M Perf Week-1.89%
Market Cap377.17M Forward P/E- EPS next Y-1.55 Insider Trans-0.34% Shs Float27.03M Perf Month11.40%
Income-42.60M PEG- EPS next Q-0.35 Inst Own64.80% Short Float10.66% Perf Quarter-14.74%
Sales3.70M P/S101.94 EPS this Y14.00% Inst Trans23.64% Short Ratio10.63 Perf Half Y-47.14%
Book/sh2.95 P/B4.57 EPS next Y-1.30% ROA-50.10% Target Price- Perf Year18.98%
Cash/sh3.28 P/C4.11 EPS next 5Y- ROE-63.70% 52W Range9.30 - 31.69 Perf YTD-15.09%
Dividend- P/FCF- EPS past 5Y- ROI-68.10% 52W High-57.46% Beta-
Dividend %- Quick Ratio6.60 Sales past 5Y- Gross Margin- 52W Low44.95% ATR1.02
Employees45 Current Ratio6.60 Sales Q/Q-30.00% Oper. Margin- RSI (14)52.41 Volatility7.49% 8.18%
OptionableYes Debt/Eq0.00 EPS Q/Q-8.70% Profit Margin- Rel Volume0.47 Prev Close13.48
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume271.15K Price13.48
Recom1.30 SMA207.97% SMA50-0.97% SMA200-28.99% Volume127,323 Change0.00%
Nov-24-20Initiated Berenberg Buy $30
Apr-09-20Initiated Stifel Buy $21
Jan-28-20Initiated BTIG Research Buy $26
Jan-22-20Initiated JMP Securities Mkt Outperform $22
Nov-25-20 12:02AM  
Nov-24-20 09:51AM  
Nov-23-20 08:00AM  
Nov-19-20 08:00AM  
Nov-17-20 04:01PM  
Nov-11-20 08:00AM  
Nov-10-20 08:00AM  
Nov-09-20 08:00AM  
Nov-03-20 06:25AM  
Oct-19-20 08:00AM  
Oct-14-20 11:30AM  
Sep-17-20 08:00AM  
Sep-15-20 08:00AM  
Sep-10-20 08:36AM  
Sep-04-20 10:07AM  
Sep-03-20 08:00AM  
Aug-31-20 04:01PM  
Aug-24-20 08:00AM  
Aug-17-20 08:00AM  
Aug-06-20 12:30PM  
Jul-28-20 08:00AM  
Jul-08-20 08:00AM  
Jul-06-20 02:36PM  
Jun-27-20 09:12PM  
Jun-15-20 08:00AM  
May-28-20 08:00AM  
May-20-20 09:01PM  
May-19-20 10:00PM  
May-18-20 08:00AM  
May-14-20 08:00AM  
May-12-20 08:00AM  
May-06-20 12:30PM  
Apr-27-20 10:02AM  
Apr-24-20 11:07AM  
Apr-23-20 07:25AM  
Apr-20-20 08:00AM  
Mar-17-20 04:05PM  
Mar-11-20 08:31AM  
Mar-10-20 08:00AM  
Mar-09-20 10:33AM  
Mar-05-20 12:30PM  
Feb-26-20 08:00AM  
Feb-19-20 08:00AM  
Feb-14-20 09:40AM  
Feb-12-20 08:00AM  
Feb-03-20 03:31AM  
Jan-30-20 10:00AM  
Jan-29-20 08:55AM  
Jan-21-20 08:00AM  
Jan-14-20 11:13AM  
Jan-13-20 10:17AM  
Jan-07-20 07:20AM  
Jan-03-20 08:22AM  
Jan-02-20 10:19AM  
Jan-01-20 12:00PM  
Dec-20-19 05:03PM  
Dec-17-19 09:11AM  
Dec-12-19 11:56AM  
Dec-11-19 09:04AM  
Dec-06-19 12:00PM  
Dec-02-19 09:02AM  
Nov-15-19 09:00AM  
Nov-12-19 04:00PM  
Nov-06-19 08:00AM  
Nov-05-19 08:00AM  
Nov-03-19 08:32AM  
Oct-30-19 08:00AM  
Oct-15-19 08:00AM  
Oct-09-19 04:30PM  
Oct-07-19 04:30PM  
Oct-02-19 08:00AM  
Sep-30-19 08:00AM  
Sep-19-19 10:48AM  
Jul-12-19 12:34PM  
Jun-03-19 08:00AM  
May-16-19 08:15AM  
May-09-19 08:00AM  
Apr-29-19 10:07AM  
Apr-08-19 08:00AM  
Mar-14-19 08:00AM  
Mar-07-19 04:30PM  
Feb-11-19 04:30PM  
Jan-31-19 10:30AM  
Jan-16-19 08:00AM  
Jan-07-19 06:46AM  
Dec-20-18 08:00AM  
Nov-14-18 08:00AM  
Nov-09-18 08:00AM  
Nov-08-18 08:00AM  
Oct-30-18 08:00AM  
Oct-24-18 08:00AM  
Oct-17-18 08:00AM  
Oct-16-18 10:02AM  
Aug-14-18 08:00AM  
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic that is in Phase I clinical trials designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, an onco-fetal viral antigen for cancers, including solid tumors and hematologic malignancies; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases, as well as a strategic research collaboration with Dr. Michael Dustin and Oxford University. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fletcher Aaron G.L.DirectorNov 24Buy12.646,54882,776165,000Nov 25 04:09 PM
Gray CameronDirectorSep 30Buy15.305,00076,500677,500Oct 01 04:13 PM
Gray CameronDirectorSep 29Buy15.005,00075,000672,500Oct 01 04:13 PM
Millar Kerri-AnnCFOAug 21Option Exercise0.006,66607,666Aug 25 04:12 PM
Suri AnishPresident and CSOAug 05Option Exercise6.428005,13635,358Aug 07 05:41 PM
Sandercock ColinSVP, General Counsel and SecAug 05Option Exercise7.5013,27499,55530,399Aug 07 05:44 PM
Suri AnishPresident and CSOAug 05Sale20.0180016,00834,558Aug 07 05:41 PM
Sandercock ColinSVP, General Counsel and SecAug 05Sale20.0013,274265,48017,125Aug 07 05:44 PM
Sandercock ColinSVP, General Counsel and SecAug 04Option Exercise7.502011,50817,326Aug 05 04:51 PM
Suri AnishPresident and CSOAug 04Option Exercise6.424002,56834,958Aug 05 04:50 PM
Suri AnishPresident and CSOAug 04Sale20.144008,05634,558Aug 05 04:50 PM
Sandercock ColinSVP, General Counsel and SecAug 04Sale20.052014,03017,125Aug 05 04:51 PM
Suri AnishPresident and CSOAug 03Option Exercise7.055,80040,91640,358Aug 05 04:50 PM
Sandercock ColinSVP, General Counsel and SecAug 03Option Exercise7.506,42548,18823,550Aug 05 04:51 PM
Sandercock ColinSVP, General Counsel and SecAug 03Sale20.006,425128,50017,125Aug 05 04:51 PM
Suri AnishPresident and CSOAug 03Sale20.015,800116,05834,558Aug 05 04:50 PM
Fletcher Aaron G.L.DirectorJun 24Buy24.887,500186,572158,452Jun 25 04:01 PM
Suri AnishPresident and CSOMar 31Option Exercise0.0016,666039,912Apr 10 06:25 PM
MARLETT CHRISTOPHER ADirectorDec 31Sale15.776,700105,659768,503Dec 31 06:26 PM
MARLETT CHRISTOPHER ADirectorDec 31Sale15.719,000141,3900Dec 31 06:26 PM
MARLETT CHRISTOPHER ADirectorDec 27Sale17.249,000155,160775,203Dec 31 06:26 PM
MARLETT CHRISTOPHER ADirectorDec 26Sale17.5319,647344,412784,203Dec 27 04:39 PM
MARLETT CHRISTOPHER ADirectorDec 23Sale16.8217,000285,940803,850Dec 27 04:39 PM
MARLETT CHRISTOPHER ADirectorDec 19Sale17.004,00068,000820,850Dec 19 05:35 PM
MARLETT CHRISTOPHER ADirectorDec 17Sale15.7320,732326,114824,850Dec 19 05:35 PM